News

Explore Moderna's growth potential with FDA-approved respiratory vaccines, strong cash reserves, and a robust pipeline.
Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 3.6% in the morning session after JPMorgan added the stock to its ...
Arexvy is currently approved for use in all individuals aged 60 and older, as well as for high-risk individuals aged 50-59.
The US Food and Drug Administration’s top vaccine official overrode agency experts in May to recommend against the broad use ...
A court battle between Regeneron and Amgen is testing the legal limits of how far drugmakers can go in using patents to ...